Q3 2025 · 13F-HR
Finepoint Capital LPholdings as filed
Filed 2025-11-13 · accession 0000904454-25-000583
$1.74B
Reported value
9
Positions
2025-09-30
Period end
The Brief · Finepoint Capital LP · Q3 2025
AI · grounded in 13F
Finepoint Capital LP established a new position in SPY valued at $804.3M. The fund also initiated new stakes in QXO for $425M and IWM for $391.2M. Additional new positions include RXO, SLDB, and ANNA.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $804.3M | 46.3% | 1,207,500 | PUT | SOLE |
| 82846H405 | QXO | QXO INC | $425.0M | 24.4% | 22,295,615 | Common | SOLE |
| 464287655 | IWM | ISHARES TR | $391.2M | 22.5% | 1,617,000 | PUT | SOLE |
| 74982T103 | RXO | RXO INC | $111.8M | 6.43% | 7,266,839 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $5.9M | 0.34% | 961,251 | Common | SOLE |
| 01444V103 | ANNA | ALEANNA INC | $115,857 | 0.01% | 27,717 | Common | SOLE |
| 01444V111 | ANNAW | ALEANNA INC | $111,720 | 0.01% | 490,000 | Common | SOLE |
| G6202B119 | MNYWW | MoneyHero Ltd | $99,972 | 0.01% | 895,000 | Common | SOLE |
| 320703408 | CLDI | CALIDI BIOTHERAPEUTICS INC | $1,584 | 0.00% | 1,042 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.